Introduction/Overview
Lucidin (CAS number: 478-08-0) is a natural anthraquinone compound derived from plants in the Rubiaceae family. As one of the important active ingredients in the Rubiaceae genus, it has received widespread attention in pharmacology and natural product chemistry in recent years due to its unique chemical structure and biological activity. Luxiding was initially identified as a mutagenic compound that can induce gene mutations in bacteria and mammalian cells, indicating its potential genetic toxicity risk. However, with the in-depth study of its molecular mechanism of action, Lucidine's multiple roles in tumor biology have gradually been revealed, especially in the regulation of therapeutic targets for breast cancer and other malignant tumors.
Breast cancer is one of the most common malignant tumors for women in the world. its complex molecular pathological mechanism and diverse therapeutic targets make the development of new natural products become an important direction of anti-cancer drug research. Lucidine shows multiple functions of regulating cell metabolism, apoptosis, signal transduction and drug tolerance by regulating multiple key molecular targets including AMPK, BCL2, STAT3, ESR2, etc., suggesting its potential application value in the treatment of breast cancer. This article will provide a systematic review of the chemical structure and physicochemical properties, plant sources and extraction methods, pharmacological activity and mechanism of action, pharmacological evaluation and pharmacokinetic characteristics of Luxidium, and explore its clinical application prospects and future research directions, aiming to provide comprehensive scientific basis for the pharmacological development of this natural product.
Chemical structure and physicochemical properties
Luxiding is a typical anthraquinone compound with a molecular formula of C15H10O5 and a molecular weight of 270.24 g/mol. Its structural core is a tricyclic anthraquinone skeleton, containing multiple hydroxyl and methoxy substituents, endowing it with unique chemical activity. The LogP value of Luxiding is 2.1748, indicating its moderate lipophilicity, which facilitates membrane penetration and in vivo distribution. Its topological polar surface area (TPSA) is 94.83 Å ², indicating that the molecule has a certain polarity that facilitates binding with biomolecules such as proteins and nucleic acids.
The low water solubility (0.1496 mg/mL) limits its solubility in aqueous phase, indicating the need to consider solubility improvement strategies in drug formulation design. The low blood-brain barrier permeability indicates that the distribution of rosuvastatin in the central nervous system is limited, which may reduce the risk of central neurotoxicity. The hERG channel inhibition experiment showed a negative result, indicating a low risk of cardiac toxicity. The Ames test result is 1.8, indicating that it has certain mutagenic activity and should be given special attention in safety assessment.
Luxiding has good chemical stability, but structural changes may occur under strong alkaline or reducing conditions, affecting its biological activity. Its UV visible spectrum exhibits typical anthraquinone absorption peaks, which facilitates its qualitative and quantitative analysis.
Plant sources and extraction methods
Luxiding is mainly found in plants of the Rubia spp. genus, especially in the roots and stems of Rubia tinctorum L., where its content is relatively high. As a traditional dye plant, madder is rich in various anthraquinone compounds in its roots, and quercetin is one of its important components. In addition to madder, other related madder plants such as Rubia cordifolia have also been reported to contain fenugreek, but at relatively low levels.
The extraction of Lu Xi Ding is usually carried out using organic solvent extraction method. Traditional methods often use methanol, ethanol, or ethyl acetate as extraction solvents, combined with ultrasound assisted extraction or hot reflux extraction techniques to improve extraction efficiency. The extraction solution was concentrated, liquid-liquid partitioned, and separated by column chromatography, and finally purified by high performance liquid chromatography (HPLC) to obtain high-purity quercetin. In recent years, supercritical CO2 extraction technology and microwave-assisted extraction technology have also been attempted to be applied to the extraction of Lu Xi Ding, with advantages such as short extraction time, low solvent consumption, and environmental friendliness.
The optimization of extraction process not only affects the yield of Lu Xi Ding, but also its purity and biological activity. Research has shown that factors such as extraction temperature, solvent polarity, and pH value have a significant impact on the stability and extraction efficiency of Luxidium. Therefore, establishing standardized extraction processes is of great significance for subsequent pharmacological research and drug development.
Pharmacological activity research
The pharmacological activities of Luxiding mainly focus on its anti-tumor, mutagenic, and antibacterial properties. Early research has found that Luxidium can induce genetic mutations in bacteria and mammalian cells, suggesting its potential genotoxicity and carcinogenic risk. In the Ames test, Luxiding showed significant mutagenic activity and requires sufficient safety evaluation before clinical application.
In terms of anti-tumor activity, Lucidine showed inhibitory effect on many tumor cell lines, especially in breast cancer cells. In vitro experiments showed that Lucidine could inhibit the proliferation of breast cancer cells and induce cell cycle arrest and apoptosis. Its anti-tumor effect may be closely related to regulating intracellular energy metabolism, anti apoptotic protein expression, and signal transduction pathways.
In addition, Lucidine can regulate the drug tolerance of breast cancer cells. By affecting the expression and function of ABC transporters (such as ABCB1 and ABCG2), rosuvastatin can reverse multidrug resistance and improve the intracellular accumulation and efficacy of chemotherapy drugs. Its anti-inflammatory and antioxidant activities also provide auxiliary mechanisms for its anti-tumor effect.
Although Luxiding has multiple pharmacological activities, its mutagenicity and potential toxicity limit its direct application as a drug. Current research focuses more on its structural modification and derivative development in order to reduce toxicity and enhance anti-tumor activity.
Mechanism of action and molecular targets
The biological effects of Luxiding are mainly achieved through the regulation of multiple targets and pathways. In the molecular mechanism research of breast cancer, the key targets involved in Lucidine include:
-
AMPK（PRKAA1）As a cellular energy sensor, AMPK regulates cellular metabolic balance. Luxiding activates the AMPK signaling pathway, promotes cellular energy metabolism reprogramming, and inhibits cancer cell proliferation and growth.
-
BCL2 The anti apoptotic protein BCL2 plays a crucial role in the survival of tumor cells. Luxiding downregulates BCL2 expression, promotes cell apoptosis, and enhances anti-tumor effects.
-
STAT3 Signal transducer and activator of transcription factor 3 (STAT3) is a key oncogene in various tumors. Luxiding inhibits the phosphorylation and nuclear translocation of STAT3, blocks its transcriptional activity, and suppresses tumor cell proliferation and invasion.
-
ESR2 (estrogen receptor beta)ESR2 plays a regulatory role in the proliferation and differentiation of breast cancer cells. Luxiding affects hormone dependent tumor growth by regulating ESR2 expression.
-
ABC transporters (ABCB1 and ABCG2)These two transporters are the main mediators of multidrug resistance. Lu Xi Ding inhibits its expression and function, reversing the drug tolerance of tumor cells.
-
PRKCA (protein kinase C alpha)Lu Xi Ding participates in cell proliferation and signal transduction, regulates PRKCA activity, and affects cell cycle and apoptosis.
-
MAPT (microtubule associated protein Tau)Related to the stability of the cytoskeleton, Luxiding may affect cell migration and invasion by regulating MAPT.
-
MMP2 (Matrix Metalloproteinase 2)Lu Xi Ding participates in the degradation and metastasis of tumor extracellular matrix, inhibits MMP2 activity, and reduces the potential for tumor metastasis.
-
LCK (lymphocyte specific protein tyrosine kinase)Lu Xi Ding may play a role in immune regulation by modulating LCK and affecting the tumor immune microenvironment.
Overall, Lu Xi Ding regulates tumor cell metabolism, apoptosis, signal transduction, and drug tolerance through multi-target synergistic effects, demonstrating a complex molecular action network and providing a theoretical basis for its anti-tumor pharmacological activity.
Evaluation of drug properties and pharmacokinetics
The pharmacological analysis of Luxiding shows that it has certain potential for drug development, but there are also several limitations. The molecular weight of 270.24 g/mol and LogP value of 2.17 comply with Lipinski's rule, indicating good drug compatibility. The TPSA is 94.83 Å ², indicating that it can moderately penetrate the cell membrane, but its low water solubility (0.1496 mg/mL) may limit oral absorption and bioavailability.
The low permeability of the blood-brain barrier reduces the risk of central nervous system side effects, but also limits its application in central diseases such as brain tumors. HERG channel inhibition is negative, indicating a low risk of cardiac toxicity, which is beneficial for safety evaluation.
The Ames test results showed that Luxiding has mutagenicity, indicating its potential genetic toxicity risk. It is necessary to reduce toxicity through structural optimization or formulation improvement in the drug development process.
At present, there is limited research on the pharmacokinetics of Luxidium. Preliminary in vivo experiments indicate poor oral absorption and short plasma half-life, mainly cleared through liver metabolism. The metabolic pathway may involve redox reactions and glucuronic acid binding. In the future, it is necessary to conduct systematic pharmacokinetic and toxicological studies to clarify their in vivo behavior and safe dosage range.
Clinical application prospects and prospects
As a natural product with multi target anti-tumor activity, Lucidine has shown great potential in the field of breast cancer treatment. Through regulating cell metabolism, apoptosis and drug tolerance related targets, it provides a new idea for overcoming chemoresistance and tumor metastasis of breast cancer.
However, the mutagenicity and low water solubility of Luxiding limit its direct clinical application. Future research should focus on the following directions:
-
Structural modification and derivative development By chemical modification, its genetic toxicity can be reduced, water solubility and bioavailability can be improved, and safe and effective derivatives of quercetin can be developed.
-
Nano carriers and drug delivery systems Using nanotechnology to improve the pharmacokinetic properties of Luxidium, achieve targeted delivery and controlled release, enhance therapeutic efficacy, and reduce side effects.
-
Combination therapy strategy Combining existing chemotherapy drugs or targeted drugs, using Luxidium to regulate drug tolerance and enhance the overall therapeutic effect.
-
In depth mechanism research Further elucidate the role of Luxiding in the tumor microenvironment and immune regulation, and explore its potential immune regulatory functions.
-
safety evaluation Conduct systematic toxicology and genotoxicity studies to ensure the safety of clinical applications.
In summary, as a candidate molecule for natural product drug development, Luxidium has good research and application prospects, but still needs to overcome challenges in terms of safety and pharmacokinetics.
Conclusion
Lucidine, as an important natural anthraquinone compound in Rubia cordifolia, has shown important value in the research of breast cancer and other malignant tumors due to its unique chemical structure and multi-target pharmacological activity. It exerts anti-tumor, drug resistance reversal, and cellular metabolism regulation effects by regulating multiple key molecular targets such as AMPK, BCL2, STAT3, reflecting the advantages of natural product multi-target therapy.
Despite its shortcomings such as mutagenicity and poor water solubility, the evaluation of its medicinal properties shows that it has certain potential for development. In the future, through structural optimization, innovative drug delivery systems, and combination therapy strategies, it is expected to overcome existing limitations and achieve its clinical application transformation.
As an important research object in the field of natural product pharmacology, the in-depth study of Luxiding not only enriches the theoretical system of the anticancer mechanism of natural products, but also provides valuable molecular templates and scientific basis for the development of new anti-tumor drugs. We look forward to more interdisciplinary cooperation and innovation in the future to promote the clinical application of Lucidine and its derivatives and benefit the majority of breast cancer patients.
